Skip to main content

Table 4 Baseline characteristics of cancer patients with or without VTE

From: Epidemiology, clinical profile and treatment patterns of venous thromboembolism in cancer patients in Taiwan: a population-based study

 

Patients without VTE

VTE (algorithm 2&)

P-value

N = 43,382

N = 473

Mean age (years)

59.52 ± 15.92

60.86 ± 14.26

0.0440*

 

No.

%

No.

%

 

Age groups (years)

    

0.0005*

  ≤18

502

1.2

1

0.2

  19 – 40

4,431

10.2

36

7.6

  41 – 60

16,847

38.8

179

37.9

  61 – 80

18,183

41.9

227

48.0

  ≥81

3,419

7.9

30

6.3

Gender

    

0.3695

  Male

22,856

52.7

259

54.8

 

  Female

20,526

47.3

214

45.2

 

Prior history of VTE

67

0.2

5

1.1

0.0011*

Hypertension

15,981

36.8

223

47.2

<0.0001*

Heart failure

1,793

4.1

31

6.6

0.0087*

Ischemic heart disease

6,005

13.8

86

18.2

0.0066*

Atrial fibrillation

649

1.5

9

1.9

0.4522

Renal insufficiency

3,270

7.5

53

11.2

0.0027*

Chronic lung disease

8,211

18.9

95

20.1

0.5229

Diabetes mellitus

7,874

18.2

97

20.5

0.1861

Stroke

2,690

6.2

30

6.3

0.8988

Degenerative & paralytic neurologic disease

3,665

8.5

47

9.9

0.2474

Rheumatologic diseases

573

1.3

12

2.5

0.0218*

Liver disease

7,959

18.4

119

25.2

0.0001*

Arterial embolism

165

0.4

7

1.5

0.0028*

Anemia

5,179

11.9

62

13.1

0.4354

Varicose veins of lower extremities

170

0.4

5

1.1

0.0418*

Peripheral vascular disease

515

1.2

9

1.9

0.1543

Pregnancy

74

0.2

2

0.4

0.1979

Infectious diseases

15,809

36.4

242

51.2

<0.0001*

Major trauma before VTE event

1260

2.9

18

3.8

0.2465

  Major spine trauma

426

1.0

6

1.3

0.4775

  Major extremity trauma

861

2.0

12

2.5

0.3924

Major surgery before VTE event

10,152

23.4

286

60.5

<0.0001*

  CNS

457

1.1

8

1.7

0.1779

  Thorax

4,706

10.9

158

33.4

<0.0001*

  Abdomen

6,094

14.1

167

35.3

<0.0001*

  Urogenital

1,397

3.2

43

9.1

<0.0001*

  Orthopedic

164

0.4

1

0.2

1.0000

Hospitalization

13,909

32.1

284

60.0

<0.0001*

Blood transfusion

3,665

8.5

49

10.4

0.1376

Active therapy

9,079

20.9

221

46.7

<0.0001*

  Chemotherapy only

5,151

11.9

182

38.5

<0.0001*

  Radiation only

214

0.5

2

0.4

1.0000

  Hormone therapy only

3,180

7.3

17

3.6

0.0020*

  Combination therapy

534

1.2

20

4.2

<0.0001*

Use of erythropoietin stimulating agent (ESA)

828

1.9

9

1.9

0.9926

Use of granulocyte colony-stimulating factor (GCSF)

1,282

3.0

41

8.7

<0.0001*

Thalidomide therapy

27

0.1

0

0.0

1.0000

Obesity

146

0.3

5

1.1

0.0243*

  1. *p-value < 0.05.
  2. &VTE algorithm 2 was based on both the hospital admission with diagnostic codes of VTE and managements of VTE (prescription of intravenous or subcutaneous (IV/SC) anticoagulants (unfractionated heparin (UFH) or low-molecular-weight heparin (LMWH)) or reimbursement codes of surgical thromboectomy) during the hospital stay.
Back to article page

BMC Cancer

ISSN: 1471-2407

Contact us